IHS Chemical Week

Regions :: North America :: U.S.

Roche to buy US biotech firm InterMune for $8.3 billion

11:21 AM MDT | August 24, 2014 | Natasha Alperowicz

Roche (Basel) said today that it has agreed to acquire InterMune (Brisbane, CA), a biotech company focused on R&D and commercializing therapies in pulmonology and orphan fibrotic diseases, for $8.3 billion. The offer represents a premium of 38% to InterMune’s closing price on 22 August and a premium of 63% to InterMune’s unaffected closing price on 12 August. Both companies' boards have approved the agreement. The transaction is expected to close this year.   Roche, under the terms of the agreement, will commence a tender offer by 29 August...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa